Evaluation and Treatment of Constipation in Children and Adolescents

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Childhood constipation is common and almost always functional without an organic etiology. Stool retention can lead to fecal incontinence in some patients. Often, a medical history and physical examination are sufficient to diagnose functional constipation. Further evaluation for Hirschsprung disease, a spinal cord abnormality, or a metabolic disorder may be warranted in a child with red flags, such as onset before one month of age, delayed passage of meconium after birth, failure to thrive, explosive stools, and severe abdominal distension. Successful therapy requires prevention and treatment of fecal impaction, with oral laxatives or rectal therapies. Polyethylene glycol–based solutions have become the mainstay of therapy, although other options, such as other osmotic or stimulant laxatives, are available. An increase in dietary fiber may improve the likelihood that laxatives can be discontinued in the future. Education is equally important as medical therapy and should include counseling families to recognize withholding behaviors; to use behavior interventions, such as regular toileting and reward systems; and to expect a chronic course with prolonged therapy, frequent relapses, and a need for close follow-up. Referral to a subspecialist is recommended only when there is concern for organic disease or when the constipation persists despite adequate therapy.

Constipation is one of the most common chronic disorders of childhood, affecting 1% to 30% of children worldwide.1 Constipation is responsible for 3% of all primary care visits for children and 10% to 25% of pediatric gastroenterology visits.2 Children with constipation cost the health care system three times as much as children without constipation,3 and the negative effect on quality of life often persists into adulthood.4

View/Print Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

A history and physical examination are usually sufficient to distinguish functional constipation from constipation caused by organic conditions.

C

2, 10

Abdominal radiography is of limited value in diagnosing chronic constipation because it lacks interobserver reliability and accuracy.

C

2, 14, 15

Polyethylene glycol–based solutions (Miralax) are effective, easy to administer, noninvasive, and well tolerated in children with constipation.

A

27, 30, 34

The addition of laxatives is more effective than behavior modification alone in children with constipation.

B

30, 31

The addition of enemas to oral laxative regimens does not improve outcomes in children with severe constipation.

B

32

Most children with functional constipation require prolonged treatment.

C

19, 35


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

A history and physical examination are usually sufficient to distinguish functional constipation from constipation caused by organic conditions.

C

2, 10

Abdominal radiography is of limited value in diagnosing chronic constipation because it lacks interobserver reliability and accuracy.

C

2, 14, 15

Polyethylene glycol–based solutions (Miralax) are effective, easy to administer, noninvasive, and well tolerated in children with constipation.

A

27, 30, 34

The addition of laxatives is more effective than behavior modification alone in children with constipation.

B

30, 31

The addition of enemas to oral laxative regimens does not improve outcomes in children with severe constipation.

B

32

Most children with functional constipation require prolonged treatment.

C

19, 35


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Definition

The Rome III criteria are the most accepted criteria for diagnosing childhood constipation (Table 1).5,6 However, the time duration does not need to be fulfilled to start therapy because there is evidence that early treatment favorably affects outcome.2

View/Print Table

Table 1.

Rome III Diagnostic Criteria for Diagnosing Functional Constipation in Children

At least two of the following in a child with a developmental age younger than four years*

Two or fewer bowel movements per week

At least one episode of incontinence per week after the acquisition of toileting skills

History of excessive stool retention

History of painful or hard bowel movements

Presence of a large fecal mass in the rectum

History of large diameter stools that may obstruct the toilet

At least two of the following in a child with a developmental age of four years or older with insufficient criteria for irritable bowel syndrome†

Two or fewer bowel movements in the toilet per week

At least one episode of fecal incontinence per week

History of retentive posturing or excessive voluntary stool retention

History of painful or hard bowel movements

Presence of a large fecal mass in the rectum

History of large diameter stools that may obstruct the toilet


*—Criteria must be fulfilled for at least one month. Accompanying symptoms may include irritability, decreased appetite, and/or early satiety, and they may disappear immediately following passage of a large stool.

†—Criteria must be fulfilled at least once a week for at least two months.

Adapted with permission from Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology . 2006; 130(5):1533, and Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology . 2006;130(5):1524.

Table 1.

Rome III Diagnostic Criteria for Diagnosing Functional Constipation in Children

At least two of the following in a child with a developmental age younger than four years*

Two or fewer bowel movements per week

At least one episode of incontinence per week after the acquisition of toileting skills

History of excessive stool retention

History of painful or hard bowel movements

Presence of a large fecal mass in the rectum

History of large diameter stools that may obstruct the toilet

At least two of the following in a child with a developmental age of four years or older with insufficient criteria for irritable bowel syndrome†

Two or fewer bowel movements in the toilet per week

At least one episode of fecal incontinence per week

History of retentive posturing or excessive voluntary stool retention

History of painful or hard bowel movements

Presence of a large fecal mass in the rectum

History of large diameter stools that may obstruct the toilet


*—Criteria must be fulfilled for at least one month. Accompanying symptoms may include irritability, decreased appetite, and/or early satiety, and they may disappear immediately following passage of a large stool.

†—Criteria must be fulfilled at least once a week for at least two months.

Adapted with permission from Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology . 2006; 130(5):1533, and Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology . 2006;130(5):1524.

Normal Defecation Patterns

Parents often worry that their child's bowel movements are too infrequent. The number of bowel movements a child has in a day decreases with age and reaches adult frequencies during the preschool years.7,8 An infant averages three to four stools a day in the first week of life, two stools a day later in infancy and the toddler years, and once a day to every other day after the preschool years.9 Many healthy breastfed infants go several days or longer without a bowel movement.2 Thus, less frequent defecation patterns may be normal and must be considered in the context of stool caliber, associated symptoms, and physical examination findings.

Etiology and Pathophysiology

Outside of the neonatal period, childhood constipation is usually functional (i.e., there is no evidence of an organic condition).2,10 Functional constipation is most commonly caused by painful bowel movements that prompt the child to voluntarily withhold stool. To avoid the passage of another painful bowel movement, the child will contract the anal sphincter or gluteal muscles by stiffening his or her body, hiding in a corner, rocking back and forth, or fidgeting with each urge to defecate. Parents often confuse these withholding behaviors as straining to defecate. Withholding of stool can lead to prolonged fecal stasis in the colon with reabsorption of fluid, causing the stool to become harder, larger, and more painful to pass. Over time, as the rectum stretches to accommodate the retained fecal mass, rectal sensation decreases, and fecal incontinence may develop. This cycle commonly coincides with toilet training, changes in routine or diet, stressful events, illness, or lack of accessible toilets, or occurs in a busy child who defers defecation.

Fecal Incontinence

Fecal incontinence is the voluntary or involuntary passage of feces in the underwear or in socially inappropriate places in a child with a developmental age of at least four years. It occurs in 1% to 4% of school-aged children and is almost always associated with underlying constipation.11 Fecal incontinence may also be associated with urinary incontinence.

The pathophysiology of fecal incontinence is poorly understood. An interaction of behavioral and physiologic factors is thought to cause long-standing functional constipation with overflow incontinence.12 Families may incorrectly confuse fecal incontinence for diarrhea or lack of attention. Fecal incontinence often improves when the stool retention is treated.13

Clinical Diagnosis

A history and physical examination are usually sufficient to distinguish functional constipation from constipation caused by an organic condition.2,10  A medical history should include the family's definition of constipation and a careful review of the frequency, consistency, and size of stools; age at onset of symptoms; timing of meconium passage after birth; recent stressors; previous and active therapies; presence of withholding behaviors, pain, or bleeding with bowel movements; abdominal pain; fecal incontinence; and systemic symptoms (Table 2).2  The presence of withholding behaviors supports the diagnosis of functional constipation. Further evaluation may be warranted in children with red flags that might suggest an organic etiology (Table 3).2

View/Print Table

Table 2.

Components of a Medical History in the Evaluation of Childhood Constipation

ComponentsClinical significance

Frequency, consistency, and size of stools

Larger, hard stools may be a sign of withholding; normal bowel movement frequency associated with symptoms may indicate irritable bowel syndrome

Age of onset

Infants younger than one month with constipation have a relatively greater likelihood of an organic etiology

Pain or bleeding with passing stools

May suggest stools that are hard enough to produce fissures or that are associated with an allergy

Abdominal pain

It is important to see if pain is relieved or affected by defecation (may suggest irritable bowel syndrome); rule out other causes because abdominal pain is often misdiagnosed as being related to constipation

Timing of first bowel movement after birth

Lack of a bowel movement in first 48 hours suggests Hirschsprung disease

Fecal incontinence

Suggests fecal impaction

Withholding behaviors

Important contributor to constipation in younger children; behavior interventions may be beneficial

Systemic symptoms (e.g., fever, vomiting, weight loss, decreased appetite)

May indicate an organic etiology, such as Hirschsprung disease

Social history, including toilet training, stressors

May be associated with the onset of constipation

Review of current and previous therapies including diet, behavior, medications

It is important to ascertain how the patient has been treated previously and if medication dosages were appropriate

Assess adherence and effectiveness of previous and current treatments

It is important to understand factors that may influence the treatment outcome


Information from reference 2.

Table 2.

Components of a Medical History in the Evaluation of Childhood Constipation

ComponentsClinical significance

Frequency, consistency, and size of stools

Larger, hard stools may be a sign of withholding; normal bowel movement frequency associated with symptoms may indicate irritable bowel syndrome

Age of onset

Infants younger than one month with constipation have a relatively greater likelihood of an organic etiology

Pain or bleeding with passing stools

May suggest stools that are hard enough to produce fissures or that are associated with an allergy

Abdominal pain

It is important to see if pain is relieved or affected by defecation (may suggest irritable bowel syndrome); rule out other causes because abdominal pain is often misdiagnosed as being related to constipation

Timing of first bowel movement after birth

Lack of a bowel movement in first 48 hours suggests Hirschsprung disease

Fecal incontinence

Suggests fecal impaction

Withholding behaviors

Important contributor to constipation in younger children; behavior interventions may be beneficial

Systemic symptoms (e.g., fever, vomiting, weight loss, decreased appetite)

May indicate an organic etiology, such as Hirschsprung disease

Social history, including toilet training, stressors

May be associated with the onset of constipation

Review of current and previous therapies including diet, behavior, medications

It is important to ascertain how the patient has been treated previously and if medication dosages were appropriate

Assess adherence and effectiveness of previous and current treatments

It is important to understand factors that may influence the treatment outcome


Information from reference 2.

View/Print Table

Table 3.

Red Flags Suggesting an Organic Cause of Constipation in Children

Red flagsSuggested diagnoses

Onset before one month of age

Congenital malformation of anorectum or spine, Hirschsprung disease, allergy, metabolic/endocrine condition

Delayed passage of meconium (more than 48 hours after birth)

Hirschsprung disease, cystic fibrosis, congenital malformation of anorectum or spine

Failure to thrive

Hirschsprung disease, malabsorption, cystic fibrosis, metabolic condition

Abdominal distension

Hirschsprung disease, impaction, neurenteric problem (e.g., pseudo-obstruction)

Intermittent diarrhea and explosive stools

Hirschsprung disease

Empty rectum

Hirschsprung disease

Tight anal sphincter

Hirschsprung disease, anorectal malformations

Pilonidal dimple covered by tuft of hair

Spinal cord abnormality

Midline pigmentary abnormalities of lower spine

Spinal cord abnormality

Abnormal neurologic examination (absent anal wink, absent cremasteric reflex, decreased lower extremity reflexes and/or tone)

Spinal cord abnormality

Occult blood in stool

Hirschsprung disease, allergy

Extraintestinal symptoms (vomiting, fever, ill-appearance)

Hirschsprung disease, neurenteric problem

Gushing of stool with rectal examination

Hirschsprung disease

No history of withholding or soiling

Hirschsprung disease, neurenteric problem, spinal cord abnormality

No response to conventional treatment

Hirschsprung disease, neurenteric problem, spinal cord abnormality


Information from reference 2.

Table 3.

Red Flags Suggesting an Organic Cause of Constipation in Children

Red flagsSuggested diagnoses

Onset before one month of age

Congenital malformation of anorectum or spine, Hirschsprung disease, allergy, metabolic/endocrine condition

Delayed passage of meconium (more than 48 hours after birth)

Hirschsprung disease, cystic fibrosis, congenital malformation of anorectum or spine

Failure to thrive

Hirschsprung disease, malabsorption, cystic fibrosis, metabolic condition

Abdominal distension

Hirschsprung disease, impaction, neurenteric problem (e.g., pseudo-obstruction)

Intermittent diarrhea and explosive stools

Hirschsprung disease

Empty rectum

Hirschsprung disease

Tight anal sphincter

Hirschsprung disease, anorectal malformations

Pilonidal dimple covered by tuft of hair

Spinal cord abnormality

Midline pigmentary abnormalities of lower spine

Spinal cord abnormality

Abnormal neurologic examination (absent anal wink, absent cremasteric reflex, decreased lower extremity reflexes and/or tone)

Spinal cord abnormality

Occult blood in stool

Hirschsprung disease, allergy

Extraintestinal symptoms (vomiting, fever, ill-appearance)

Hirschsprung disease, neurenteric problem

Gushing of stool with rectal examination

Hirschsprung disease

No history of withholding or soiling

Hirschsprung disease, neurenteric problem, spinal cord abnormality

No response to conventional treatment

Hirschsprung disease, neurenteric problem, spinal cord abnormality


Information from reference 2.

Physical examination should include a review of growth parameters, an abdominal examination, an external examination of the perineum and perianal area, an evaluation of the thyroid and spine, and a neurologic evaluation for appropriate reflexes (cremasteric, anal wink, patellar). A digital examination of the anorectum is recommended to assess for perianal sensation, anal tone, rectum size, anal wink, and amount and consistency of stool in the rectum. However, in children with normal neonatal courses or clear withholding behaviors, or in whom trauma is suspected, the rectal examination may be deferred. A test for occult blood in the stool should be performed in all infants with constipation and in any child with constipation who has pain, failure to thrive, diarrhea, or a family history of colon cancer or polyps. The presence of a hard mass in the lower abdomen combined with a dilated rectum filled with hard stool indicates fecal impaction.

Abdominal radiography is of limited value in diagnosing chronic constipation because it lacks interobserver reliability and accuracy.2,14,15 It should be reserved for specific clinical circumstances in which a rectal examination is unreasonable (e.g., in a child with a history of trauma) or the diagnosis is uncertain.

Differential Diagnosis

Table 4 outlines the differential diagnosis of constipation in children and the recommended diagnostic evaluations.2 The age of the patient must be carefully considered.

View/Print Table

Table 4.

Differential Diagnosis of Constipation in Children

ConditionsRecommended diagnostic evaluation

Functional constipation

History and physical examination; no testing

Anatomic malformations of the colon and rectum

Imperforate anus, anal or colonic stenosis, anteriorly displaced anus

Physical examination, barium enema

Spinal cord abnormalities

Meningomyelocele, spinal cord tumor or trauma, tethered cord

Spinal magnetic resonance imaging, anorectal manometry, urodynamics

Metabolic conditions

Hypothyroidism

Thyroid studies

Hypercalcemia, hyperkalemia

Serum calcium and potassium levels

Diabetes mellitus

Fasting glucose level

Diabetes insipidus

Serum and urine osmolarity

Neuropathic gastrointestinal disorders

Hirschsprung disease, internal anal sphincter achalasia

Anorectal manometry, rectal suction biopsy

Visceral myopathy/neuropathy

Colonic manometry

Drug use/toxin exposure

Opiates, phenobarbital, anticholinergics and attention-deficit/hyperactivity disorder drugs, antacids and sucralfate (Carafate), antidepressants, antihypertensives

History, drug level

Lead toxicity

Lead level

Other systemic disorders

Celiac disease

Tissue transglutaminase

IgA, total IgA, endoscopy

Cystic fibrosis

Sweat test

Cow's milk protein intolerance

Cow's milk elimination

Connective tissue disorder, mitochondrial disorders

Special testing

Psychiatric disorders

Psychological and psychiatric evaluation


IgA = immunoglobulin A.

Information from reference 2.

Table 4.

Differential Diagnosis of Constipation in Children

ConditionsRecommended diagnostic evaluation

Functional constipation

History and physical examination; no testing

Anatomic malformations of the colon and rectum

Imperforate anus, anal or colonic stenosis, anteriorly displaced anus

Physical examination, barium enema

Spinal cord abnormalities

Meningomyelocele, spinal cord tumor or trauma, tethered cord

Spinal magnetic resonance imaging, anorectal manometry, urodynamics

Metabolic conditions

Hypothyroidism

Thyroid studies

Hypercalcemia, hyperkalemia

Serum calcium and potassium levels

Diabetes mellitus

Fasting glucose level

Diabetes insipidus

Serum and urine osmolarity

Neuropathic gastrointestinal disorders

Hirschsprung disease, internal anal sphincter achalasia

Anorectal manometry, rectal suction biopsy

Visceral myopathy/neuropathy

Colonic manometry

Drug use/toxin exposure

Opiates, phenobarbital, anticholinergics and attention-deficit/hyperactivity disorder drugs, antacids and sucralfate (Carafate), antidepressants, antihypertensives

History, drug level

Lead toxicity

Lead level

Other systemic disorders

Celiac disease

Tissue transglutaminase

IgA, total IgA, endoscopy

Cystic fibrosis

Sweat test

Cow's milk protein intolerance

Cow's milk elimination

Connective tissue disorder, mitochondrial disorders

Special testing

Psychiatric disorders

Psychological and psychiatric evaluation


IgA = immunoglobulin A.

Information from reference 2.

YOUNG INFANTS

The likelihood of an organic etiology for constipation is relatively greater in infants younger than six months, and particularly in those younger than three months. Hirschsprung disease must be considered in infants with delayed passage of meconium (more than 48 hours after birth) or other red flags, even in the setting of normal findings on barium enema examination. Hirschsprung disease is the most common cause of lower intestinal obstruction in neonates. A delayed diagnosis can result in enterocolitis, a potentially fatal complication that causes fever; abdominal distension; and explosive, bloody diarrhea.16 Patients with suspected Hirschsprung disease should be referred to a medical center with a pediatric gastroenterologist and surgeon for confirmatory testing with rectal suction biopsy.

If Hirschsprung disease is excluded in an infant with delayed passage of meconium, cystic fibrosis and other anatomic malformations should be considered. The physical examination of a young infant should assess the position and patency of the anus and include a neurologic examination to evaluate for congenital anomalies of the anus and spine (e.g., anteriorly displaced anus, anal stenosis, imperforate anus, spina bifida, tethered cord). Breastfed infants require special consideration because in the absence of red flags or other medical issues, they require no further workup for infrequent bowel movements.

OLDER CHILDREN

Further evaluation is indicated in older children with red flags or with intractable constipation despite strict adherence to therapy. Laboratory studies may be performed to evaluate for systemic diseases, such as thyroid disease, other metabolic diseases, celiac disease, or lead toxicity. Motility studies (e.g., anorectal manometry) can assess for sphincter abnormalities, such as Hirschsprung disease or a nonrelaxing internal anal sphincter. Magnetic resonance imaging of the spine may be necessary to evaluate for a tethered cord, spinal cord tumor, or sacral agenesis.17 A trial of a cow's milk–free diet may also be considered because constipation can be caused by intolerance to cow's milk, especially in young children with anal fissures.2,18

Treatment

The treatment of functional constipation requires parental education, behavior interventions, measures to ensure that bowel movements occur at normal intervals with good evacuation, close follow-up, and adjustment of medication and evaluation as necessary. Algorithms for the evaluation and management of constipation in infants and older children are presented in Figures 1 and 2.2,10,19

View/Print Figure

Constipation in Infants Younger than Six Months

Figure 1.

Algorithm for evaluation and management of constipation in infants younger than six months.

Information from references 2,10, and 19.

Constipation in Infants Younger than Six Months


Figure 1.

Algorithm for evaluation and management of constipation in infants younger than six months.

Information from references 2,10, and 19.

View/Print Figure

Constipation in Children Six Months and Older

Figure 2.

Algorithm for evaluation and management of constipation in children six months and older.

Information from references 2,10, and 19.

Constipation in Children Six Months and Older


Figure 2.

Algorithm for evaluation and management of constipation in children six months and older.

Information from references 2,10, and 19.

EDUCATION AND BEHAVIOR MODIFICATION

Education is the first step in treatment. Educational materials for parents on constipation and fecal soiling are available at http://www.gikids.org. It is important to explain that fecal incontinence occurs from involuntary overflow of stool and not from voluntary defiance. Behavior modification with regular toileting (for five to 10 minutes) after meals combined with a reward system is often helpful. Parents should be encouraged to maintain a positive and supportive attitude throughout treatment and expect gradual improvement with occasional relapses.

Although behavior modification and education are important, intensive behavior therapy does not seem to add to treatment success, except in rare cases in which the patient has underlying behavior problems.20 Biofeedback has not been shown to be effective in children with functional constipation.2,21

DIETARY CHANGES

Dietary changes are often advised in children with constipation.21 An increased intake of fluids and absorbable and nonabsorbable carbohydrates (e.g., sorbitol in prune, pear, and apple juice) can help soften stools, particularly in infants. The recommended dosage of prune juice for infants is 2 oz per day. It can be diluted with 2 oz of water for palatability. Studies have shown that children with constipation have a lower fiber intake than other children. An increased intake of dietary fiber may improve the likelihood that a child will be able to discontinue laxative therapies.22 The addition of a probiotic (e.g., Lactobacillus GG) may be helpful in some children with functional constipation, although the studies are preliminary.23

DISIMPACTION

When fecal impaction is present, disimpaction with oral or rectal medication is required before initiation of maintenance therapy. Oral medications are less invasive but require more patient cooperation and may be slower to relieve symptoms. A number of therapies are available (Table 5).2,2426 The advent of polyethylene glycol–based solutions (Miralax) has changed the initial approach to constipation in children because they are effective, easy to administer, noninvasive, and well tolerated.27 Rectal therapies and polyethylene glycol are similarly effective in the treatment of fecal impaction in children.28 Although some evidence supports polyethylene glycol as first-line treatment, the overall data do not clearly demonstrate superiority of one laxative.29

View/Print Table

Table 5.

Therapies for Disimpaction in Children

TherapyDosage

Oral

Osmotics

Polyethylene glycol 3350 (Miralax)*

1.5 g per kg per day

Polyethylene glycol solution (Golytely)*

25 mL per kg per hour via nasogastric lavage

Magnesium citrate

< 6 years: 2 to 4 mL per kg per day

6 to 12 years of age: 100 to 150 mL per day

> 12 years: 150 to 300 mL per day

Stimulants

Senna (Senokot)

2 to 6 years of age: 2.5 to 7.5 mL (8.8 mg per 5 mL); ½ to 1 ½ tablets (8.6 mg per tablet) per day

6 to 12 years of age: 5 to 15 mL; 1 to 2 tablets per day

Bisacodyl (Dulcolax)

≥ 2 years: 5 to 15 mg (1 to 3 tablets) per day in a single dose

Lubricants

Mineral oil

15 to 30 mL per year of age per day

Rectal agents

Enemas (one per day)

Saline

5 to 10 mL per kg

Mineral oil

15 to 30 mL per year of age up to 240 mL

Phosphate soda

2 to 12 years of age: 66-mL enema (should not to be used in children < 2 years because of the risk of electrolyte abnormality)

> 12 years: 133 mL

Suppository (one per day)

Bisacodyl

≥ 2 years: 5 to 10 mg (½ to 1 suppository)

Glycerin*

½ to 1 infant suppository; adult suppository for those older than 6 years

Other

Manual (used rarely; general anesthesia needed)


*—May be used in infants < 1 year.

Information from references 2, and 24 through 26.

Table 5.

Therapies for Disimpaction in Children

TherapyDosage

Oral

Osmotics

Polyethylene glycol 3350 (Miralax)*

1.5 g per kg per day

Polyethylene glycol solution (Golytely)*

25 mL per kg per hour via nasogastric lavage

Magnesium citrate

< 6 years: 2 to 4 mL per kg per day

6 to 12 years of age: 100 to 150 mL per day

> 12 years: 150 to 300 mL per day

Stimulants

Senna (Senokot)

2 to 6 years of age: 2.5 to 7.5 mL (8.8 mg per 5 mL); ½ to 1 ½ tablets (8.6 mg per tablet) per day

6 to 12 years of age: 5 to 15 mL; 1 to 2 tablets per day

Bisacodyl (Dulcolax)

≥ 2 years: 5 to 15 mg (1 to 3 tablets) per day in a single dose

Lubricants

Mineral oil

15 to 30 mL per year of age per day

Rectal agents

Enemas (one per day)

Saline

5 to 10 mL per kg

Mineral oil

15 to 30 mL per year of age up to 240 mL

Phosphate soda

2 to 12 years of age: 66-mL enema (should not to be used in children < 2 years because of the risk of electrolyte abnormality)

> 12 years: 133 mL

Suppository (one per day)

Bisacodyl

≥ 2 years: 5 to 10 mg (½ to 1 suppository)

Glycerin*

½ to 1 infant suppository; adult suppository for those older than 6 years

Other

Manual (used rarely; general anesthesia needed)


*—May be used in infants < 1 year.

Information from references 2, and 24 through 26.

MAINTENANCE THERAPY

The goal of maintenance therapy is to avoid reaccumulation of stool by maintaining soft bowel movements, preferably occurring once a day. Given a robust placebo response, there is insufficient evidence to support the effectiveness of laxative therapies over placebo in the treatment of childhood constipation.30 However, most studies show that the addition of laxatives is usually necessary and more effective than behavior modification alone.31 Although the use of enemas has been advocated in the past, recent studies have shown that the addition of enemas to oral laxative regimens does not improve outcomes in children with severe constipation.32

Table 6 summarizes maintenance therapies.2,2426 Overall, polyethylene glycol achieves equal or better treatment success than other laxatives, such as lactulose or milk of magnesia,30,33,34 although it may be associated with more episodes of fecal incontinence.27 The dose of polyethylene glycol can be adjusted according to treatment response. Maintenance doses of medications need to be continued for several weeks to months after a regular bowel habit is established. Children who are toilet training should remain on laxatives until toilet training is well established.

View/Print Table

Table 6.

Maintenance Therapies for Children with Constipation

TherapyDosageAdverse effects

Osmotics

Polyethylene glycol 3350 (Miralax)*†

0.5 to 0.8 g per kg up to 17 g per day

Anaphylaxis, flatulence

Lactulose†

1 mL per kg per day once or twice per day, single dose or in two divided doses

Abdominal cramps, flatulence

Magnesium hydroxide

< 2 years: 0.5 mL per kg per day

Infants are susceptible to magnesium overdose (hypermagnesemia, hyperphosphatemia, hypocalcemia)

2 to 5 years of age: 5 to 15 mL per day

6 to 11 years of age: 15 to 30 mL per day

≥ 12 years: 30 to 60 mL per day

Medication may be given at bedtime or in divided doses

Sorbitol (e.g., prune juice)†

1 to 3 mL per kg once or twice per day in infants

Similar to lactulose

Stimulants

Senna (Senokot)†

1 month to 2 years of age: 1.25 to 2.5 mL (2.2 to 4.4 mg) at bedtime (< 5 mL per day); 8.8 mg per day

Idiosyncratic hepatitis, melanosis coli, hypertrophic osteoarthropathy, analgesic nephropathy

2 to 6 years of age: 2.5 to 3.75 mL (4.4 to 6.6 mg) or ½ tablet (4.3 mg) at bedtime (< 7.5 mL or 1 tablet per day)

6 to 12 years of age: 5 to 7.5 mL (8.8 to 13.2 mg) or 1 tablet (8.6 mg) at bedtime (< 15 mL or 2 tablets per day)

> 12 years: 10 to 15 mL (26.4 mg) or 2 tablets (17.2 mg) at bedtime (< 30 mL or 4 tablets per day)

Bisacodyl (Dulcolax)

> 2 years: 5 to 15 mg (1 to 3 tablets) once per day

Abdominal cramps, diarrhea, hypokalemia, abnormal rectal mucosa, proctitis (rare), urolithiasis (case reports)

Lubricants

Mineral oil

Children: 5 to 15 mL per day

Lipoid pneumonia if aspirated, theoretical interference with absorption of fat-soluble substances, foreign body reaction in intestine

Adolescents: 15 to 45 mL per day


*—First-line therapy.

†—May be used in infants < 1 year.

Information from references 2, and 24 through 26.

Table 6.

Maintenance Therapies for Children with Constipation

TherapyDosageAdverse effects

Osmotics

Polyethylene glycol 3350 (Miralax)*†

0.5 to 0.8 g per kg up to 17 g per day

Anaphylaxis, flatulence

Lactulose†

1 mL per kg per day once or twice per day, single dose or in two divided doses

Abdominal cramps, flatulence

Magnesium hydroxide

< 2 years: 0.5 mL per kg per day

Infants are susceptible to magnesium overdose (hypermagnesemia, hyperphosphatemia, hypocalcemia)

2 to 5 years of age: 5 to 15 mL per day

6 to 11 years of age: 15 to 30 mL per day

≥ 12 years: 30 to 60 mL per day

Medication may be given at bedtime or in divided doses

Sorbitol (e.g., prune juice)†

1 to 3 mL per kg once or twice per day in infants

Similar to lactulose

Stimulants

Senna (Senokot)†

1 month to 2 years of age: 1.25 to 2.5 mL (2.2 to 4.4 mg) at bedtime (< 5 mL per day); 8.8 mg per day

Idiosyncratic hepatitis, melanosis coli, hypertrophic osteoarthropathy, analgesic nephropathy

2 to 6 years of age: 2.5 to 3.75 mL (4.4 to 6.6 mg) or ½ tablet (4.3 mg) at bedtime (< 7.5 mL or 1 tablet per day)

6 to 12 years of age: 5 to 7.5 mL (8.8 to 13.2 mg) or 1 tablet (8.6 mg) at bedtime (< 15 mL or 2 tablets per day)

> 12 years: 10 to 15 mL (26.4 mg) or 2 tablets (17.2 mg) at bedtime (< 30 mL or 4 tablets per day)

Bisacodyl (Dulcolax)

> 2 years: 5 to 15 mg (1 to 3 tablets) once per day

Abdominal cramps, diarrhea, hypokalemia, abnormal rectal mucosa, proctitis (rare), urolithiasis (case reports)

Lubricants

Mineral oil

Children: 5 to 15 mL per day

Lipoid pneumonia if aspirated, theoretical interference with absorption of fat-soluble substances, foreign body reaction in intestine

Adolescents: 15 to 45 mL per day


*—First-line therapy.

†—May be used in infants < 1 year.

Information from references 2, and 24 through 26.

Stimulant laxatives (e.g., bisacodyl [Dulcolax], sennosides) may be required in some children, although data on their use in children are limited. The lack of liquid formulations limits the practical use of stimulant laxatives in younger children. In the primary care setting, stimulant laxatives should be reserved for rescue therapy when an osmotic laxative is ineffective. Patients requiring constant administration of stimulant laxatives should be evaluated further.

Long-Term Prognosis

Most children with functional constipation require prolonged treatment and have frequent relapses.19 Studies have shown that only 60% of children with constipation achieve treatment success after one year of therapy. Children with fecal incontinence or who are younger than four years at onset of constipation are particularly at risk of poor long-term outcomes.35

Referral

Referral to a pediatric gastroenterologist may be needed when a child with constipation has red flags for organic disease or the constipation is unresponsive to adequate therapy. Subspecialists may pursue newer medical therapies, such as lubiprostone (Amitiza), which acts on chloride channels in the intestine,36 or onabotulinumtoxinA (Botox) injected into a nonrelaxing sphincter.37 Surgical therapies, such as antegrade colonic enemas, have also been shown to improve continence in children with intractable constipation.38 Motility testing often helps guide management in children with intractable constipation.19,39 Although most children have functional constipation, it is important to reevaluate those who do not follow the expected course.

Data Sources: A PubMed search was completed using the keywords constipation, child, pediatric, functional constipation, and incontinence. Also searched were the Cochrane database, Essential Evidence Plus, and guidelines from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the National Institute for Health and Care Excellence. Search dates: February 24, 2012, and October 2013.

The Authors

show all author info

SAMUEL NURKO, MD, is director of the Motility and Gastrointestinal Disorders Center at Boston (Mass.) Children's Hospital, and is an associate professor in the hospital's Department of Medicine....

LORI A. ZIMMERMAN, MD, is an attending physician in gastroenterology and nutrition in the Department of Medicine at Boston Children's Hospital.

Author disclosure: No relevant financial affiliations.

Address correspondence to Samuel Nurko, MD, Boston Children's Hospital, 300 Longwood Ave., Boston, MA 02115 (e-mail: samuel.nurko@childrens.harvard.edu). Reprints are not available from the authors.

REFERENCES

show all references

1. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol. 2006;101(10):2401–2409....

2. Tabbers MM, Dilorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):265–281.

3. Liem O, Harman J, Benninga M, Kelleher K, Mousa H, Di Lorenzo C. Health utilization and cost impact of childhood constipation in the United States. J Pediatr. 2009;154(2):258–262.

4. Bongers ME, van Wijk MP, Reitsma JB, Benninga MA. Long-term prognosis for childhood constipation: clinical outcomes in adulthood. Pediatrics. 2010;126(1):e156–e162.

5. Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130(5):1527–1537.

6. Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006;130(5):1519–1526.

7. Tunc VT, Camurdan AD, Ilhan MN, Sahin F, Beyazova U. Factors associated with defecation patterns in 0-24-month-old children. Eur J Pediatr. 2008;167(12):1357–1362.

8. Corazziari E, Staiano A, Miele E, Greco L; Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Bowel frequency and defecatory patterns in children: a prospective nationwide survey. Clin Gastroenterol Hepatol. 2005;3(11):1101–1106.

9. Fontana M, Bianchi C, Cataldo F, et al. Bowel frequency in healthy children. Acta Paediatr Scand. 1989;78(5):682–684.

10. Bardisa-Ezcurra L, Ullman R, Gordon J; Guideline Development Group. Diagnosis and management of idiopathic childhood constipation: summary of NICE guidance. BMJ. 2010;340:c2585.

11. van der Wal MF, Benninga MA, Hirasing RA. The prevalence of encopresis in a multicultural population. J Pediatr Gastroenterol Nutr. 2005;40(3):345–348.

12. van den Berg MM, Bongers ME, Voskuijl WP, Benninga MA. No role for increased rectal compliance in pediatric functional constipation. Gastroenterology. 2009;137(6):1963–1969.

13. Brazzelli M, Griffiths PV, Cody JD, Tappin D. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. Cochrane Database Syst Rev. 2011;(12):CD002240.

14. Moylan S, Armstrong J, Diaz-Saldano D, Saker M, Yerkes EB, Lindgren BW. Are abdominal x-rays a reliable way to assess for constipation? J Urol. 2010;184(4 suppl):1692–1698.

15. Pensabene L, Buonomo C, Fishman L, Chitkara D, Nurko S. Lack of utility of abdominal x-rays in the evaluation of children with constipation: comparison of different scoring methods. J Pediatr Gastroenterol Nutr. 2010;51(2):155–159.

16. Marty TL, Matlak ME, Hendrickson M, Black RE, Johnson DG. Unexpected death from enterocolitis after surgery for Hirschsprung's disease. Pediatrics. 1995;96(1 pt 1):118–121.

17. Rosen R, Buonomo C, Andrade R, Nurko S. Incidence of spinal cord lesions in patients with intractable constipation. J Pediatr. 2004;145(3):409–411.

18. Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. N Engl J Med. 1998;339(16):1100–1104.

19. Nurko S. Advances in the management of pediatric constipation. Curr Gastroenterol Rep. 2000;2(3):234–240.

20. van Dijk M, Bongers ME, de Vries GJ, Grootenhuis MA, Last BF, Benninga MA. Behavioral therapy for childhood constipation: a randomized, controlled trial. Pediatrics. 2008;121(5):e1334–e1341.

21. Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011;128(4):753–761.

22. Maffei HV, Vicentini AP. Prospective evaluation of dietary treatment in childhood constipation: high dietary fiber and wheat bran intake are associated with constipation amelioration. J Pediatr Gastroenterol Nutr. 2011;52(1):55–59.

23. Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol. 2011;17(34):3916–3921.

24. Epocrates. http://www.epocrates.com. Accessed April 3, 2014.

25. Tschudy MM, Arcara KM; Johns Hopkins Hospital. Harriet Lane Handbook: A Manual for Pediatric House Officers. 19th ed. Philadelphia, Pa.: Elsevier; 2012.

26. Biggs WS, Dery WH. Evaluation and treatment of constipation in infants and children. Am Fam Physician. 2006;73(3):469–477.

27. Nurko S, Youssef NN, Sabri M, et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. J Pediatr. 2008;153(2):254–261.

28. Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics. 2009;124(6):e1108–e1115.

29. Pijpers MA, Tabbers MM, Benninga MA, Berger MY. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures [published correction appears in Arch Dis Child. 2009;94(8):649]. Arch Dis Child. 2009;94(2):117–131.

30. Candy D, Belsey J. Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review. Arch Dis Child. 2009;94(2):156–160.

31. Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr. 2005;146(3):359–363.

32. Bongers ME, van den Berg MM, Reitsma JB, Voskuijl WP, Benninga MA. A randomized controlled trial of enemas in combination with oral laxative therapy for children with chronic constipation. Clin Gastroenterol Hepatol. 2009;7(10):1069–1074.

33. Thomson MA, Jenkins HR, Bisset WM, et al. Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study [published correction appears in Arch Dis Child. 2008;93(1):93]. Arch Dis Child. 2007;92(11):996–1000.

34. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;(7):CD007570.

35. van Ginkel R, Reitsma JB, Büller HA, van Wijk MP, Taminiau JA, Benninga MA. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology. 2003;125(2):357–363.

36. Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB Jr, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56(9):2639–2645.

37. Chumpitazi BP, Fishman SJ, Nurko S. Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter. Am J Gastroenterol. 2009;104(4):976–983.

38. Siddiqui AA, Fishman SJ, Bauer SB, Nurko S. Long-term follow-up of patients after antegrade continence enema procedure. J Pediatr Gastroenterol Nutr. 2011;52(5):574–580.

39. Nurko S. What's the value of diagnostic tools in defecation disorders? J Pediatr Gastroenterol Nutr. 2005;41(suppl 1):S53–S55.



 

Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Related Content


More in Pubmed

MOST RECENT ISSUE


Oct 1, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article